An interventional study of LFD and PED Shield in Intracranial Aneurysms and Flow Diverter, sponsored by Henan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Henan Provincial People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.
Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 23rd largest by planned enrollment of the 49 interventional ones that give a count, is one of 9 that started in 2026, is one of 37 with no phase, reaches primary completion later than 25 of the 41 other live ones, and was the 96th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:
Xuanwu Hospital, Beijing · Sites in China
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 22–80
Duan Chuanzhi · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 9
First in 2005; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 196 is above the median of 104 across 208 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 188 across the 49 interventional studies, 600 across the 51 observational. Of the 27 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 100 have an industry lead sponsor. The 10 most frequent:
Henan Provincial People's Hospital is the lead sponsor of 63 studies on the registry; 33 are open to participants now.
Henan Provincial People's Hospital has 1 study filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
7 of the studies in Intracranial Aneurysm with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06943729Huashan HospitalClinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms | 2026-12-30 |
| NCT06364293Beijing Tiantan HospitalAn Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm | 2026-12-31 |
| NCT07089862Beijing Tiantan HospitalINdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) | 2026-12-31 |
| NCT07674004Henan Provincial People's HospitalSurface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes | 2027-02-28 |
| NCT07707076Nanfang Hospital, Southern Medical UniversityFlow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 100 studies in Intracranial Aneurysm with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Flow diverters (FDs) have become a mainstay of endovascular therapy for unruptured intracranial aneurysms (UIAs), yet their implantation carries an inherent risk of ischemic complications. The Pipeline Flex Embolization Device with Shield Technology (PED Shield) and the Lattice Flow Diverter (LFD) are two surface-modified FDs that have shown promising efficacy for mitigating procedure-related ischemic events in prior single-arm or retrospective series. Nevertheless, head-to-head comparative data between these two surface-modified flow diverters remain scarce, and prospective randomized clinical trials are warranted to corroborate their differential performance in lowering ischemic complication risks.This prospective, multicenter randomized controlled trial (RCT) was designed to compare the efficacy of PED Shield versus LFD in reducing ischemic complications after endovascular treatment of UIAs. A total of 196 eligible participants who meet the predefined inclusion and exclusion criteria will be enrolled in the trial. The primary outcome measure is the incidence of new diffusion-weighted imaging (DWI)-positive lesions on brain magnetic resonance imaging (MRI) within 48 hours after the procedure. The secondary outcome measures consist of perioperative symptomatic ischemic events, all-cause mortality and disability rate during the follow-up period, delayed aneurysm rupture at the 6-month follow-up, complete aneurysm occlusion rate, incidence of major in-stent stenosis (stenosis degree >50%) at the 6-month follow-up, and the number of new DWI-positive lesions within 48 hours post-procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects Treated with the PED Shield for Intracranial Aneurysms
Device: PED Shield
Subjects Treated with the LFD for Intracranial Aneurysms
Device: LFD
Subjects who meet the inclusion and exclusion criteria will undergo randomization after signing the study informed consent form. When a subject is randomly assigned to the LFD group, the operator will implant this flow diverter following standardized surgical procedures.
Subjects who meet the inclusion and exclusion criteria will undergo randomization after signing the study informed consent form. When a subject is randomly assigned to the PED Shield group, the operator will implant this flow diverter following standardized surgical procedures.
The incidence of patients with new positive diffusion-weighted imaging (DWI) lesions
The proportion of patients with newly developed DWI hyperintensities detected on magnetic resonance imaging (MRI) within 48 hours after the surgical procedure.
Time frame: Within 48 Hours postoperatively.
Symptomatic neurological ischemic events
Symptomatic neurological ischemic events related to the target aneurysm, mainly including transient ischemic attack (TIA) and acute cerebral infarction, as adjudicated by the clinical event committee.
Time frame: 0-7 days postoperatively
Mortality and major disability rate during follow-up
Proportion of patients with a modified Rankin Scale (mRS) score \> 3 or an increase of ≥ 2 points in mRS score from baseline, as adjudicated by the clinical event committee.
Time frame: 180 (±30) days
Rate of delayed aneurysm rupture
Incidence of intracranial hemorrhage caused by delayed rupture of the target aneurysm, as adjudicated by the clinical event committee. The time calculation starts from the first day after surgery.
Time frame: 180 (±30) days
Aneurysm complete occlusion rate
Complete occlusion rate of the target aneurysm assessed via the Raymond-Roy classification scale.
Time frame: 180 (±30) days
Incidence of target parent artery in-stent stenosis (>50%)
In-stent stenosis of the target parent artery was defined as stenosis degree \>50%, which was evaluated by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) at 6 months after surgery.
Time frame: 180 (±30) days
Number of DWI positive lesions
The number of DWI positive lesions detected on postoperative magnetic resonance imaging (MRI).
Time frame: Within 48 hours postoperatively
Plan to share: Yes
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.
Of 59 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 134. This study's planned 9 months is below that.
Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Provincial People's Hospital